Phosphodiesterase 5 inhibitors in vascular systemic disorders

被引：4

作者：

Allanore, Yannick ^{[1
]}

机构：

[1] Univ Paris 05, INSERM U1016, Serv Rhumatol, Hop Cochin, F-75014 Paris, France

来源：

JOINT BONE SPINE | 2012年 / 79卷 / 04期

关键词：

Phosphodiesterase; Nitric oxide; Pulmonary hypertension; Raynaud's phenomenon; Sildenafil; Tadalafil; PULMONARY ARTERIAL-HYPERTENSION; RAYNAUDS-PHENOMENON RESISTANT; DOUBLE-BLIND; SILDENAFIL; THERAPY; TADALAFIL; SCLEROSIS; EFFICACY;

D O I：

10.1016/j.jbspin.2011.12.009

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：338 / 340

页数：3

共 20 条

[1]

Badesch DB, 2007, J RHEUMATOL, V34, P2417

[2] Management of Raynaud's phenomenon and digital ulcers in systemic sclerosis [J].

Botzoris, Vasileios ;

Drosos, Alexandros A. .

JOINT BONE SPINE, 2011, 78 (04) :341-346

[3] Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study [J].

Brueckner, Claudia S. ;

Becker, Mike O. ;

Kroencke, Thomas ;

Huscher, Doerte ;

Scherer, Hans Ulrich ;

Worm, Margitta ;

Burmester, Gerd ;

Riemekasten, Gabriela .

ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (08) :1475-1478

[4] Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy [J].

Fries, R ;

Shariat, K ;

von Wilmowsky, H ;

Böhm, M .

CIRCULATION, 2005, 112 (19) :2980-2985

[5] Sildenafil citrate therapy for pulmonary arterial hypertension [J].

Galiè, N ;

Ghofrani, HA ;

Torbicki, A ;

Barst, RJ ;

Rubin, LJ ;

Badesch, D ;

Fleming, T ;

Parpia, T ;

Burgess, G ;

Branzi, A ;

Grimminger, F ;

Kurzyna, M ;

Simonneau, G .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (20) :2148-2157

[6] Tadalafil Therapy for Pulmonary Arterial Hypertension [J].

Galie, Nazzareno ;

Brundage, Bruce H. ;

Ghofrani, Hossein A. ;

Oudiz, Ronald J. ;

Simonneau, Gerald ;

Safdar, Zeenat ;

Shapiro, Shelley ;

White, R. James ;

Chan, Melanie ;

Beardsworth, Anthony ;

Frumkin, Lyn ;

Barst, Robyn J. .

CIRCULATION, 2009, 119 (22) :2894-U65

[7] Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension - A randomized prospective study [J].

Ghofrani, HA ;

Voswinckel, R ;

Reichenberger, F ;

Olschewski, H ;

Haredza, P ;

Karadas, B ;

Schermuly, RT ;

Weissmann, N ;

Seeger, W ;

Grimminger, F .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 44 (07) :1488-1496

[8] Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial [J].

Ghofrani, HA ;

Wiedemann, R ;

Rose, F ;

Schermuly, RT ;

Olschewski, H ;

Weissmann, N ;

Gunther, A ;

Walmrath, D ;

Seeger, W ;

Grimminger, F .

LANCET, 2002, 360 (9337) :895-900

[9] Contemporary management of Raynaud's phenomenon and digital ischaemic complications [J].

Herrick, Ariane L. .

CURRENT OPINION IN RHEUMATOLOGY, 2011, 23 (06) :555-561

[10] Modified-Release Sildenafil Reduces Raynaud's Phenomenon Attack Frequency in Limited Cutaneous Systemic Sclerosis [J].

Herrick, Ariane L. ;

van den Hoogen, Frank ;

Gabrielli, Armando ;

Tamimi, Nihad ;

Reid, Carol ;

O'Connell, Damian ;

Vazquez-Abad, Maria-Dolores ;

Denton, Christopher P. .

ARTHRITIS AND RHEUMATISM, 2011, 63 (03) :775-782

← 1 2 →